The group's principal activity is to develop novel immune therapy products for cancers and infectious diseases. The group manufactures the product multikine(TM) using proprietary cell culture technologies that involve a combination of natural human interleukin-2 and certain other cytokines. Multikine is developed as a treatment for human papilloma virus (hpv) induced cervical dysplasia in HIV infected women and for head and neck cancer. L.e.a.p.s. Is another product, a t-cell modulation technology that is being tested as potential treatment and preventive vaccine against various diseases like aids, chronic genital and oral herpes, malaria, colon cancer, breast cancer and autoimmune myocarditis.
